Duan Zhitang (Beijing) International Pharmaceutical Technology Development Co., Ltd. was founded in June 2009, the company has been committed to the inheritance and promotion of traditional Chinese medicine culture, focusing on the development and application of court secret recipe antiviral products, we have achieved a number of scientific and technological achievements in the field of antivirus, and participated in the treatment of tens of thousands of clinical patients with various types of virus infection (all cases can be traced back) The curative effect and negative conversion rate have made worldwide breakthroughs.
The following are the types and effects of our true participation:
1. HPV human papillomavirus, the negative conversion rate was more than 95%, the negative cycle was mild for about 1 month, and the severe rate was about 5 months.
2. HIV HIV, the treatment cycle is about 4 months, the therapeutic effect can effectively control the viral load to zero, and restore the human immunity to the normal value.
3. During the period of SARS SARS, all sequelae were cleared after 3 days of continuous use of ICU, in severe patients.
4. COVID-19 (NCP), the first batch of samples we sent to Indonesia, has been sent to Indonesia. It only takes about a week to turn negative, and the negative conversion rate is 100%.
That's it! Duan Zhitang is willing to contribute the scientific research achievements of our lives to all mankind in order to save more lives.
Duan Zhitang (Beijing) International Pharmaceutical Technology Development Co., Ltd.
1460472234@qq.com
Penafian: Artikel ini diterbitkan semula dari media lain. Tujuan mencetak semula adalah untuk menyampaikan lebih banyak maklumat. Ini tidak bermakna laman web ini bersetuju dengan pandangannya dan bertanggungjawab ke atas keasliannya, dan tidak menanggung tanggungjawab undang-undang. Semua sumber di laman web ini dikumpulkan di Internet. Tujuan perkongsian adalah untuk pembelajaran dan rujukan sahaja. Sekiranya terdapat pelanggaran hak cipta atau harta intelek, sila tinggalkan mesej.
© Hak cipta 2009-2020 Rangkaian Berita Melayu Hubungi kami SiteMap